Table of contents

Clinical/translational cancer immunotherapy

• Original research: Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) (25 August, 2022)

  Benny Johnson, Cara L Haymaker, Edwin R Parra, Luisa Maren Solis Soto, Xuemei Wang, Jane V Thomas, Arvind Dasari, Van K Morris, Kanwal Raghav, Eduardo Vilar, Bryan K Kee, Cathy Eng, Christine M Parseghian, Robert A Wolff, Younghee Lee, Daniele Lorenzini, Caddie Laberiano-Fernandez, Anuj Verma, Wenhua Lang, Ignacio I Wistuba, Andrew Futreal, Scott Kopetz, Michael J Overman
• Original research:

  Antitumor efficacy of ⁹⁰Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors

  (24 August, 2022)

  Hemanth K Potluri, Carolina A Ferreira, Joseph Grudzinski, Christopher Massey, Eduardo Aluicio-Sarduy, Jonathan W Engle, Ohyun Kwon, Ian R Marsh, Bryan P Bednarz, Reinier Hernandez, Jamey P Weichert, Douglas G McNeel
• Original research: Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments (24 August, 2022)

  Sylvain Nguyen, Mathieu F Chevalier, Sulayman Benmerzoug, Valérie Cesson, Anna K Schneider, Sonia-Cristina Rodrigues-Dias, Florence Dartiguenave, Ilaria Lucca, Patrice Jichlinski, Beat Roth, Denise Nardelli-Haefliger, Laurent Derré
• Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection (24 August, 2022)

  Zeynep Eroglu, Kristy K Broman, John F Thompson, Amanda Nijhuis, Tina J Hieken, Lisa Kottschade, Jeffrey M Farma, Meghan Hotz, Jeremiah Deneve, Martin Fleming, Edmund K Bartlett, Avinash Sharma, Lesly Dossett, Tasha Hughes, David E Gyorki, Jennifer Downs, Giorgos Karakousis, Yun Song, Ann Lee, Russell S Berman, Alexander van Akkooi, Emma Stahlie, Dale Han, John Vetto, Georgia Beasley, Norma E Farrow, Jane Yuet Ching Hui, Marc Moncrieff, Jenny Nobes, Kirsten Baecher, Matthew Perez, Michael Lowe, David W Ollila, Frances A Collichio, Roger Olofsson Bagge, Jan Mattsson, Hidde M Kroon, Harvey Chai, Jyri Teras, James Sun, Michael J Carr, Ankita Tandon, Nalan Akgul Babacan, Younchul Kim, Mahrukh Naqvi, Jonathan Zager, Nikhil I Khushalani
• Original research: Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC (24 August, 2022)

  Kun Li, Yihang Gong, Dongbo Qiu, Hui Tang, Jian Zhang, Zenan Yuan, Yingqi Huang, Yunfei Qin, Linsen Ye, Yang Yang
• Original research: Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016 (23 August, 2022)

  Tamara A Sussman, Rebecca Knackstedt, Wei Wei, Pauline Funchain, Brian R Gastman
• Original research: Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study (18 August, 2022)

  Shailender Bhatia, Paul Nghiem, S Phani Veeranki, Alejandro Vanegas, Kristina Lachance, Lisa Tachiki, Kevin Chiu, Emily Boller, Murtuza Bharmal
• Original research: Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy (18 August, 2022)

  Laura Schäkel, Salahuddin Mirza, Riekje Winzer, Vittoria Lopez, Riham Idris, Haneen Al-Hroub, Julie Pelletier, Jean Sévigny, Eva Tolosa, Christa E Müller
• Original research: Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial (17 August, 2022)

  Karim Fizazi, Margitta Retz, Daniel P Petrylak, Jeffrey C Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschäbitz, Mauricio Burotto, Hakim Mahammedi, Gwenaelle Gravis, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Daniel Castellano, Aude Fléchon, Fred Saad, Marc-Oliver Grimm, David R Shaffer, Andrew J Armstrong, Prabhu Bhagavatheeswaran, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Jun Li, Andrea Loehr, Russell K Pachynski
• Original research: Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors (8 August, 2022)

  Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E Bauman, Rhonda L Bitting, Alexander Starodub, Antonio Jimeno, David A Reardon, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Deepa S Subramaniam, Jeanny B Aragon-Ching, Thomas R Hawthorne, Tracey Rawls, Michael Yellin, Tibor Keler
• Original research: Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma (5 August, 2022)

  Ana Costa, Cécile Thirant, Amira Kramdi, Cécile Pierre-Eugène, Caroline Louis-Brennetot, Orphée Blanchard, Didier Surdez, Nadege Gruel, Eve Lapouble, Gaëlle Pierron, Deborah Sitbon, Hervé Brisse, Arnaud Gauthier, Paul Fréneaux, Mylène Bohec, Virginie Raynal, Sylvain Baulande, Renaud Leclere, Gabriel Champenois, Andre Nicolas, Didier Meseure, Angela Bellini, Aurelien Marabelle, Birgit Geoerger, Fatima Mechta-Grigoriou, Gudrun Schleiermacher, Laurie Menger, Olivier Delattre, Isabelle Janoueix-Lerosey